Exploring potential therapeutic combinations for castration-sensitive prostate cancer using supercomputers: a proof...

Area of Science:

• Computational biology
• Oncology
• Pharmacology

Background:

• Castration-sensitive prostate cancer (CSPC) poses a significant therapeutic challenge, often progressing to an incurable castration-resistant stage.
• Identifying effective combination therapies is crucial for improving CSPC treatment outcomes and preventing disease progression.

Purpose of the Study:

• To introduce Vini, a novel computational tool designed to predict the efficacy of drug combinations at the intracellular level for CSPC.
• To leverage integrated biological and chemical databases for comprehensive drug combination analysis.

Main Methods:

• Vini integrates data from multiple databases including KEGG, DrugBank, Pubchem, Protein Data Bank, Uniprot, NCI-60, and COSMIC.
• The tool analyzes intracellular drug interactions, target genes, proteins, and small molecules involved in cancer development.
• It comprehensively considers all known molecular players and their interrelations in cancer pathogenesis.

Main Results:

• Vini predicts novel, previously unexplored combination therapies for CSPC.
• Identified triple drug combinations revealed common key targets: ALK, BCL-2, mTOR, DNA, and the androgen axis.
• These findings suggest potential therapeutic strategies to prevent CSPC progression to castration-resistant prostate cancer.

Conclusions:

• The Vini computational model offers an innovative approach to discovering effective treatments for CSPC.
• Predicted combination therapies could serve as promising candidates for clinical validation.
• This strategy may lead to breakthrough therapies for castration-sensitive prostate cancer, potentially halting its progression.